Tessa Romero
Stock Analyst at JP Morgan
(4.44)
# 331
Out of 5,124 analysts
73
Total ratings
52.63%
Success rate
24.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $19.97 | +90.29% | 1 | Dec 19, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $37 → $20 | $27.22 | -26.52% | 7 | Nov 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $11.29 | +32.86% | 8 | Nov 20, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $57 → $60 | $44.82 | +33.87% | 3 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $44.05 | +6.70% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $3.51 | +7,392.88% | 1 | Nov 18, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $33 → $31 | $26.71 | +16.06% | 11 | Nov 17, 2025 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $19.56 | -13.09% | 7 | Nov 14, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $24.82 | +37.01% | 11 | Nov 14, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Underweight | n/a | $1.79 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $53 | $63.54 | -16.59% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $9.93 | +0.70% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $27.15 | +39.96% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $14.85 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $18.27 | +58.73% | 3 | Aug 13, 2024 |
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $19.97
Upside: +90.29%
Agios Pharmaceuticals
Nov 21, 2025
Maintains: Neutral
Price Target: $37 → $20
Current: $27.22
Upside: -26.52%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $11.29
Upside: +32.86%
Xenon Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $57 → $60
Current: $44.82
Upside: +33.87%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $44.05
Upside: +6.70%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $3.51
Upside: +7,392.88%
ACADIA Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $33 → $31
Current: $26.71
Upside: +16.06%
Dyne Therapeutics
Nov 14, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $19.56
Upside: -13.09%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $24.82
Upside: +37.01%
Neumora Therapeutics
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.79
Upside: -
Jun 9, 2025
Maintains: Overweight
Price Target: $71 → $53
Current: $63.54
Upside: -16.59%
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $9.93
Upside: +0.70%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $27.15
Upside: +39.96%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $14.85
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $18.27
Upside: +58.73%